| Q34537628 | Anti-TNF inhibits the airways neutrophilic inflammation induced by inhaled endotoxin in human |
| Q38051306 | Challenge models to assess new therapies in chronic obstructive pulmonary disease |
| Q35557425 | Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease |
| Q35919812 | Cilostazol Decreases Ethanol-Mediated TNFalpha Expression in RAW264.7 Murine Macrophage and in Liver from Binge Drinking Mice |
| Q81123561 | Development of an inhaled endotoxin challenge protocol for characterizing evoked cell surface phenotype and genomic responses of airway cells in allergic individuals |
| Q36806616 | Dissociation between systemic and pulmonary anti-inflammatory effects of dexamethasone in humans |
| Q36468155 | Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects |
| Q28482881 | LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing |
| Q34640736 | Low-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development. |
| Q36042965 | Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects |
| Q37425642 | PDE4 inhibitors - a review of the current field |
| Q52599800 | The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. |
| Q51758105 | Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge. |